Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy

Inclusion Criteria: Male or female outpatients at least 18 years of age with a primary (the condition that is most central to the patient's current distress) psychiatric diagnosis of PTSD as defined by DSM-IV criteria Patients must have remained symptomatic (CGI-S > or = 3) and a score of at least 6 on the SPRINT after a minimum of 7 sessions of prolonged exposure (delivered within 6 weeks) to be eligible for randomized treatment. Exclusion Criteria: Serious medical illness or instability for which hospitalization may be likely within the next 3 months Pregnant or lactating women or those of childbearing potential not using medically accepted forms of contraception Concurrent use of other psychotropic medications Lifetime diagnosis of schizophrenia or any other psychotic disorder, mental retardation, organic mental disorders, or bipolar disorder Obsessive-Compulsive Disorder, eating disorders, or alcohol/substance abuse disorders within the last 6 months A current primary diagnosis of major depression, dysthymia, social anxiety disorder, and generalized anxiety disorder A history of hypersensitivity or poor response to paroxetine or those using antidepressants, buspirone, or beta-blockers within 2 weeks of randomization Concurrent dynamic or supportive psychotherapy if started within 2 months prior to onset of study entry